№ 4 (189) 2024 р. С. 72–77

ЦУКРОВИЙ ДІАБЕТ ТА COVID-19: МОЖЛИВИЙ ЗВ’ЯЗОК ТА РИЗИКИ РОЗВИТКУ (ОГЛЯД ЛІТЕРАТУРИ)

Є. І. Юрченко, Г. Ф. Степанов, І. В. Юрченко

Одеський національний медичний університет, Одеса, Україна

DOI 10.32782/2226-2008-2024-4-12

Цукровий діабет 2 типу (ЦД 2) становить майже 90–95% всіх випадків діабетів і має глобальну розповсюдженість. Пацієнти з ЦД 2 входять до групи ризику тяжкого перебігу COVID-19 зі швидким прогресуванням запального процесу, потребою госпіталізації у відділення інтенсивної терапії, частим розвитком тяжких ускладнень, які впливають на прогноз хвороби. Імовірним є зв’язок між інфікуванням вірусом SARS-CoV-2 та підвищеним ризиком виникнення нового діабету 2 типу. Дискутабельними є питання щодо термінів тривалості гіперглікемії та виникнення нового діабету у пацієнтів, які перехворіли на COVID-19, що потребує проведення подальшого спостереження та обстеження таких пацієнтів.

Ключові слова: цукровий діабет 2 типу, ризик розвитку, SARS-CoV-2, COVID-19.

REFERENCES

  1. IDF Diabetes Atlas. 10th edition. 2021. https://diabetesatlas.org/.
  2. Sun H, Saeedi P, Karuranga S et al. IDF Diabetes Atlas: Global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045. Diabetes Research and Clinical Practice. 2022; 183: 109119. https://doi.org/10.1016/j. diabres.2021.109119.
  3. Public Health Center of the Ministry of Health of Ukraine. Available from: https://phc.org.ua/kontrol-zakhvoryuvan/ neinfekciyni-zakhvoryuvannya.
  4. Atlas: Diabet v Ukrayini. Available from: https://diabetesatlas.com.ua/.
  5. American Diabetes Association Professional Practice Committee. 2. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes. 2022. Diabetes Care. 2022; 45(1): 17–38. https://doi.org/10.2337/dc22-S002.
  6. Abu-Ashour W, Twells LK, Valcour JE, Gamble JM. Diabetes and the occurrence of infection in primary care: a matched cohort study. BMC Infect Dis. 2018; 18(1): 67. doi: 10.1186/s12879-018-2975-2.
  7. Mor A, Berencsi K, Nielsen JS, et al. Rates of Community-based Antibiotic Prescriptions and Hospital-treated Infections in Individuals With and Without Type 2 Diabetes: A Danish Nationwide Cohort Study, 2004–2012. Clin Infect Dis. 2016; 63:501. doi: 10.1093/cid/ciw345.
  8. Steenblock C, Schwarz PEH, Ludwig B, et al. COVID-19 and metabolic disease: mechanisms and clinical management. Lancet Diabetes Endocrinol. 2021 Nov.; 9(11): 786–798. doi: 10.1016/S2213-8587(21)00244-8.
  9. World Health Organization. Coronavirus worldwide graphs — recovered and discharged 2020 [updated July 28; cited 2020 Jul 29]. Available from: https://www.worldometers.info/coronavirus/worldwide-graphs/#recovered.
  10. Guan W-j, Ni Z-yi, Hu Y, et al. Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J Med. 2020; 382: 1708–1720. dоі: 10.1056/NEJMoa2002032.
  11. Li B, Yang J, Zhao F et al. Prevalence and impact of cardiovascular metabolic diseases on COVID-19 in China. Clinical Research in Cardiology. 2020; 109: 531–538. doi: 10.1007/s00392-020-01626-9.
  12. Li R, Shen M, Yang Q et al. Global Diabetes Prevalence in COVID-19 Patients and Contribution to COVID-19 – Related Severity and Mortality: A Systematic Review and Meta-analysis. Diabetes Care. 2023; 46(4): 890–897. https://doi.org/10.2337/dc22-1943.
  13. Khan MMA, Khan N, Mustagir G, Rana J, Islam S, Kabir I. Effects of underlying morbidities on the occurrence of deaths in COVID-19 patients: A systematic review and meta-analysis. Journal of health glob. 2020; 10(2): 020503 doi: 10.7189/ jogh.10.020503.
  14. Yan Y, Yang Y, Wang F et al. Clinical characteristics and outcomes of patients with severe COVID-19 with diabetes. BMJ Open Diabetes Res Care. 2020; 8(1): 001343 doi: 10.1136/bmjdrc-2020-001343.
  15. Bode B., Garrett V., Messler J., et al. Glycemic characteristics and clinical outcomes of COVID-19 patients hospitalized in the United States. J Diabetes Sci Technol. 2020; 14 (4): 813–821. doi.org/10.1177/1932296820924469.
  16. Guo W, Li M, Dong Ya et al. Diabetes is a risk factor for the progression and prognosis of COVID-19. Diabetes Metabolism Research and Reviews. 2020; 36(7): 3319. Available from: https://doi.org/10.1002/dmrr.3319.
  17. Zhao Zh, Wang Sh, Ma W et al. Diabetes mellitus increases the incidence of deep vein thrombosis after total knee arthroplasty. Archives of Orthopaedic and Trauma Surgery. 2014; 134(1): 79–83 doi: 10.1007/s00402-013-1894-3.
  18. Kim Na-y, Ha E, Moon JS, Lee Y-H, Choi E Y. Acute Hyperglycemic Crises with Coronavirus Disease-19: Case Reports. Diabetes & Metabolism Journal. 2020; 44(2): 349–353. DOI: https://doi.org/10.4093/dmj.2020.0091.
  19. Mastromauro C, Blasetti A, Primavera M, et al. Peculiar characteristics of new-onset Type 1 Diabetes during COVID-19 pandemic. Ital J Pediatr. 2022; 48: 26 https://doi.org/10.1186/s13052-022-01223-8.
  20. Ng SM, Woodger K, Regan F, et al. Presentation of newly diagnosed type 1 diabetes in children and young people during COVID-19: a national UK survey. BMJ Paediatrics Open. 2020; 4: 000884. doi: 10.1136/bmjpo-2020-000884.
  21. Heaney A.I, Griffin G.D., Simon E. L. Newly diagnosed diabetes and diabetic ketoacidosis precipitated by COVID-19 infection. The American Journal of Emergency Medicine. 2020; 38 (11): 2491.e3–2491.e4 doi.org/10.1016/j.ajem.2020.05.114.
  22. Pal R., Banerjee M., Yadav U., Bhattacharjee S. Clinical profile and outcomes in COVID-19 patients with diabetic ketoacidosis: A systematic review of literature. Diabetes Metab Syndr. 2020; 14(6): 1563–1569. doi: 10.1016/ j.dsx.2020.08.015.
  23. Misra S, Barron E, Vamos E et al. Temporal trends in emergency admissions for diabetic ketoacidosis in people with diabetes in England before and during the COVID-19 pandemic: a population-based study. Lancet Diabetes Endocrinol. 2021; 9(10): 671–680. https://doi.org/10.1016/S2213-8587(21)00208-4.
  24. Lizzo JM, Goyal A, Gupta V. Adult Diabetic Ketoacidosis. [Updated 2 May 2023]. In StatPearls [Internet]; StatPearls Publishing: Treasure Island, FL, USA, 2023. Available online: https://www.ncbi.nlm.nih.gov/books/NBK560723/.
  25. Ghash A, Misra A. Marked hyperglycemia and ketosis in a non-obese patient with new-onset diabetes and very mild COVID-19 symptoms: a case report. Diabetes Metab Syndr. 2021; 15: 213–4. doi: 10.1016/j.dsx.2020.12.036.
  26. Li J, Wang X, Chen J, Zuo X, Zhang H, Deng A. COVID-19 infection may cause ketosis and ketoacidosis. Diabetes Obes 2020; 22(10): 1935–1941. doi.org/10.1111/dom.14057.
  27. Kitabchi AE, Umpierrez GE, Miles JM, Fisher JN. Hyperglycemic crises in adult patients with diabetes. Diabetes Care. 2009; 32(7): 1335–1343. doi: 10.2337/dc09-9032.
  28. Khan AA, Ata F, Iqbal P, Bashir M, Kartha A. Clinical and biochemical predictors of intensive care unit admission among patients with diabetic ketoacidosis. World J. Diabetes. 2023; 14(3): 271–278. doi: 10.4239/wjd.v14.i3.271.
  29. Rubino F, Amiel SA, Zimmet P, et al. New-Onset Diabetes in Covid-19. N Engl J Med. 2020; 383 (8): 789–790. doi: 10.1056/NEJMc2018688.
  30. Bornstein SR, Rubino F, Khunti K, et al. Practical recommendations for the management of diabetes in patients with COVID-19. Lancet Diabetes Endocrinol. 2020; 8(6): 546–550. doi: https://doi.org/10.1016/S2213-8587(20)30152-2.
  31. Coppelli A, Giannarelli R, Aragona M. et al. Hyperglycemia at Hospital Admission Is Associated With Severity of the Prognosis in Patients Hospitalized for COVID-19: The Pisa COVID-19 Study. Diabetes Care. 2020; 43(10): 2345–2348. https://doi.org/10.2337/dc20-1380.
  32. Li H, Tian S, Chen T, et al. Newly diagnosed diabetes is associated with a higher risk of mortality than known diabetes in hospitalized patients with COVID-19. Diabetes Obes Metab. 2020; 22 (10): 1897–1906. https://doi.org/10.1111/dom.14099.
  33. Plummer M.P, Finnis M.E, Phillips L.K. et al. Stress Induced Hyperglycemia and the Subsequent Risk of Type 2 Diabetes in Survivors of Critical Illness. PLoS One. 2016; 11(11): 0165923. doi: 10.1371/journal.pone.0165923.
  34. Ayoubkhani D, Khunti K, Nafilyan V, Maddox T, Humberstone B, Diamond I, Banerjee A. Post-covid syndrome in individuals admitted to hospital with COVID-19: retrospective cohort study. 2021; 372: 693 doi: https://doi.org/10.1136/bmj.n693.
  35. Sathish T, Kapoor N, Cao Y, Tapp RJ, Zimmet P. Proportion of newly diagnosed diabetes in COVID-19 patients: a systematic review and metaanalysis. Diabetes Obes Metab. 2021; 23(3): 870–874. doi: 10.1111/dom.14269.
  36. Shrestha DB, Budhathoki P, Raut S, et al. New-onset diabetes in COVID-19 and clinical outcomes: a systematic review and meta-analysis. World J Virol. 2021; 10 (5): 275–287. doi: 10.5501/wjv.v10.i5.275.
  37. Sathish T, Tapp RJ, Cooper ME, Zimmet P. Potential metabolic and inflammatory pathways between COVID-19 and new-onset diabetes. Diabetes Metab. 2021; 47(2): 101204. doi: 10.1016/j.diabet.2020.10.002.
  38. Akarsu C, Karabulut M, Aydin H, et al. Association between Acute Pancreatitis and COVID-19: could pancreatitis be the missing piece of the puzzle about increased mortality rates? J Invest Surg. 2022; 35 (1): 119–125. https://doi.org/10.1080/ 08941939.2020.1833263.
  39. Liu F, Long X, Zhang B, Zhang W, Chen X, Zhang Z. ACE2 Expression in Pancreas May Cause Pancreatic Damage After SARS-CoV-2 Infection. AGA Journals. 2020; 18(9): 2128–2130. doi: 10.1016/j.cgh.2020.04.040.
  40. He X, Liu Chenshu, Peng Jiangyun et al. COVID-19 induces new-onset insulin resistance and lipid metabolic dysregulation via regulation of secreted metabolic factors. Signal Transduction and Targeted Therapy. 2021; 6: 427 https://doi.org/10.1038/ s41392-021-00822-x.
  41. Santos A, Magro D.O, Evangelista-Poderoso R., Saad M JA. Diabetes, obesity, and insulin resistance in COVID-19: molecular interrelationship and therapeutic implications. Diabetol Metab Syndr. 2021; 13:23 https://doi.org/10.1186/ s13098-021-00639-2.
  42. Xu AY, Wang SH, Duong TQ. Patients with prediabetes are at greater risk of developing diabetes 5 months postacute SARS-CoV-2 infection: a retrospective cohort study. BMJ Open Diab Res Care. 2023; 11: 003257. https://doi.org/10.1136/ bmjdrc-2022-003257.
  43. Birabaharan M, Kaelber DC, Pettus JH, Smith DM. Risk of new-onset type 2 diabetes in 600 055 people after COVID-19: a cohort study. Diabetes Obes Metab. 2022; 24 (6): 1176–1179. doi: 10.1111/dom.14659.
  44. Birabaharan M, Kaelber DC, Pettus JH, Smith DM. Risk of new-onset type 2 diabetes in 600 055 people after COVID-19: a cohort study. Diabetes Obes Metab. 2022; 24 (6): 1176–1179. doi: 10.1111/dom.14659.
  45. Choi JH, Kim KM, Song K, Seo G. H. Risk for Newly Diagnosed Type 2 Diabetes Mellitus after COVID-19 among Korean Adults: A Nationwide Matched Cohort Study. Endocrinol Metab (Seoul). 2023; 38(2): 245–252. doi: 10.3803/ EnM.2023.1662.
  46. Banerjee M, Pal R, Dutta S. Risk of incident diabetes post-COVID-19: a systematic review and meta-analysis. Prim Care Diabetes. 2022; 16: 591–593. doi: 10.1016/j.pcd.2022.05.009.
  47. Reges O, Test T, Hoshen M, et al. Time-varying association of acute and post-acute COVID-19 with new-onset diabetes mellitus among hospitalized and non-hospitalized patients. BMJ Open Diabetes Res. 2023; 11: 003052 doi: 10.1136/ bmjdrc-2022-003052.
  48. Xie Y, Al-Aly Z. Risks and burdens of incident diabetes in long COVID: a cohort study. Lancet Diabetes Endocrinol. 2022; 10(5): 311–321. doi: 10.1016/s2213-8587(22)00044-4.
  49. Zhang J, Shu T, Zhu R, Yang F, Zhang B, Lai X. The Long-Term Effect of COVID-19 Disease Severity on Risk of Diabetes Incidence and the Near 1-Year Follow-Up Outcomes among Postdischarge Patients in Wuhan. Clin. Med. 2022; 11(11): 3094. https://doi.org/10.3390/jcm11113094.
  50. Cromer SJ, Colling C, Schatoff D et al. Newly diagnosed diabetes vs. pre-existing diabetes upon admission for COVID-19: Associated factors, short-term outcomes, and long-term glycemic phenotypes. J Diabetes Complicat. 2022; 36(4): 108145. https://doi.org/10.1016/j.jdiacomp.2022.108145.
  51. Gupta RD, Atri A, Mondal S et al. Characterizing progressive beta-cell recovery after new-onset DKA in COVID-19 provoked A-β+ KPD (ketosis-prone diabetes): A prospective study from Eastern India. J Diabetes Complications. 2022; 36 (3): 108100. https://doi.org/10.1016/j.jdiacomp.2021.108100.
Переглянути публікацію PDF